Prevention of renal osteodystrophy in predialysis patients.

[1]  E. Slatopolsky,et al.  RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  G. Chertow,et al.  Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  J. Gogusev,et al.  Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. , 1997, Kidney international.

[4]  R. Lepage,et al.  Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. , 1996, The Journal of clinical endocrinology and metabolism.

[5]  Aníbal Ferreira,et al.  PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats , 1996 .

[6]  E. Bonucci,et al.  Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study , 1996 .

[7]  E. Ritz,et al.  Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  Y. Tsukamoto,et al.  Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  J. Kanis,et al.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure , 1995, BMJ.

[10]  J. Halse,et al.  Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  W. Weimar,et al.  Effects of 24r,25‐dihydroxyvitamin D3 in combination with 1α‐hydroxyvitamin D3 in predialysis renal insufficiency: Biochemistry and histomorphometry of cancellous bone , 1995 .

[12]  V. Chinchilli,et al.  A prospective double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol , 1994 .

[13]  S. Ortolani,et al.  Calcitriol and calcium carbonate therapy in early chronic renal failure. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  G. Segre,et al.  Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. , 1994, Kidney international.

[15]  A. Torres,et al.  Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  K. Kurokawa,et al.  Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. , 1993, The Journal of clinical investigation.

[17]  E. Bonucci,et al.  Two-site immunoradiometric intact parathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bone lesions in predialysis chronic renal failure. , 1993, The Journal of laboratory and clinical medicine.

[18]  B. Boudailliez,et al.  Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment? , 1992, Bone.

[19]  E. Ritz,et al.  Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  K. Schaefer,et al.  The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  A. Dusso,et al.  Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. , 1990, The American journal of physiology.

[22]  J. Silver,et al.  Regulation of parathyroid cell gene expression in experimental uremia. , 1990, Journal of the American Society of Nephrology : JASN.

[23]  A. Dusso,et al.  Metabolic clearance rate and production rate of calcitriol in uremia. , 1989, Kidney international.

[24]  E. Ogata,et al.  Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. , 1989, The Journal of clinical investigation.

[25]  H. Malluche,et al.  1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. , 1989, Kidney international.

[26]  L. Schiller,et al.  Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. , 1989, The Journal of clinical investigation.

[27]  M. Holick,et al.  Vitamin D and the kidney. , 1987, Kidney international.

[28]  A. Korkor.  Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. , 1987, The New England journal of medicine.

[29]  J. Russell,et al.  Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. , 1986, Endocrinology.

[30]  J. Kopp,et al.  Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. , 1986, The Journal of clinical endocrinology and metabolism.

[31]  E. Slatopolsky,et al.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. , 1986, The Journal of clinical investigation.

[32]  J. Delmez,et al.  Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. , 1986, The New England journal of medicine.

[33]  G. Dunea,et al.  Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. , 1986, ASAIO transactions.

[34]  E. Bonucci,et al.  Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. , 1986, Mineral and electrolyte metabolism.

[35]  J. Russell,et al.  Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. W. Wright,et al.  Who gets renal bone disease before beginning dialysis? , 1985, British medical journal.

[37]  D. Sherrard,et al.  Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. , 1984, The Journal of pediatrics.

[38]  R. Morris,et al.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. , 1984, The Journal of clinical investigation.

[39]  F. Eke,et al.  Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure. , 1983, Archives of disease in childhood.

[40]  A. Fournier,et al.  Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. , 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[41]  A. Fabris,et al.  Effects of dietary protein and phosphorus restriction on the progression of early renal failure. , 1982, Kidney international.

[42]  H. Harter,et al.  Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. , 1982, Kidney international.

[43]  J. Kopple,et al.  Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. , 1982, Kidney international.

[44]  R. Morris,et al.  Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. , 1982, Kidney international.

[45]  C. Christiansen,et al.  IS 1,25‐DIHYDROXY‐CHOLECALCIFEROL HARMFUL TO RENAL FUNCTION IN PATIENTS WITH CHRONIC RENAL FAILURE? , 1981, Clinical endocrinology.

[46]  S. Massry,et al.  Effects of long-term therapy with calcitriol in patients with moderate renal failure. , 1980, Archives of internal medicine.

[47]  A. Alfrey,et al.  Metabolism and toxicity of aluminum in renal failure. , 1980, The American journal of clinical nutrition.

[48]  H. E. Hansen,et al.  1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. , 1980, Clinical nephrology.

[49]  H. DeLuca,et al.  Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. , 1978, The New England journal of medicine.

[50]  D. Cook,et al.  THE EFFECT OF lα‐HYDROXYVITAMIN D3 IN PRE‐DIALYSIS RENAL BONE DISEASE , 1977, Clinical endocrinology.

[51]  M. Haussler,et al.  Basic and clinical concepts related to vitamin D metabolism and action (second of two parts). , 1977, The New England journal of medicine.

[52]  M. Christensen,et al.  CONTROLLED TRIAL OF 1α-HYDROXYCHOLECALCIFEROL IN CHRONIC RENAL FAILURE , 1976, The Lancet.

[53]  E. Ritz,et al.  Bone histology in incipient and advanced renal failure. , 1976, Kidney international.

[54]  J. H. Kaye,et al.  Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism. , 1975, The Journal of clinical endocrinology and metabolism.

[55]  A. Norman,et al.  Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. , 1972, The New England journal of medicine.

[56]  H. DeLuca,et al.  Vitamin D Metabolism: The Role of Kidney Tissue , 1971, Science.

[57]  W. J. Johnson,et al.  Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors. , 1971, The Journal of clinical investigation.

[58]  W. F. Taylor,et al.  Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone. , 1971, The Journal of clinical investigation.

[59]  E. Kaplan,et al.  The role of phosphate in the secretion of parathyroid hormone in man. , 1970, The Journal of clinical investigation.

[60]  N. Bricker,et al.  The control of phosphate excretion in uremia. , 1966, The Journal of clinical investigation.

[61]  R. Goldman,et al.  Phosphorus excretion in renal failure. , 1954, The Journal of clinical investigation.